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SUPPLEMENTARY NOTES
ABSTRACT
Epithelial ovarian cancer (EOC) continues to be the leading cause of the death among gynecological malignancies, owing to the lack of preventive strategies, early diagnostic methods or effective therapies. Detailed understanding of molecular changes, such as, somatic mutations, in ovarian cancer holds the promise of g reatly contributing to the understanding of ovarian cancer pathogenesis, with obvious implications in development of new biomarkers, prevention strategies and therapyMicro-RNAs (miRNAs) are endogenous non-coding ~22 nucleotide (nt) R NAs, whose ex pression ap pears to be el evated i n normal tissues, com pared to in tu mors, su ggesting th at silencing o f miRNA m ay be a hallmark of h uman cancers . M iRNA m isexpression m ight be due t o genetic mutations i n miRNA ge nes an d t heir responsive elements in target g enes. To test th is h ypothesis, In th e p ast year, we id entified 7 g enetic mutations in 5 0 selecte d h uman miRNA ge nes and t heir responsive el ements i n t arget g enes i n 75 OC tum or tissues. Their correl ations with clinical o utcome u nder investigation. 
SUBJECT TERMS
INTRODUCTION
Epithelial o varian canc er (EOC) c ontinues to be the leading cause of the death among gynecological m alignancies, owing to the lack of pr eventive strategies, early diagnostic methods or effective therapies. Detailed understanding of molecular changes, such as, somatic mutations, in ovarian cancer holds the promise of greatly contributing to the understanding of ovarian cancer pathog enesis, with obvious i mplications in development of new biomarkers, prevention strategies and therapy. It is our hope that this investigation will y ield signatures of somatic mutations that will h elp us predict d isease outcome and possibly address crucial clinical management issues, such as identification of patients what will respond to standard chemothe rapy, in need for alternate frontline drugs. Micro-RNAs ( miRNAs) are endogenous non-coding ~22 nucleotide (nt) RNAs, whose expression appears to be elevated in n ormal tissues, com pared to in tum ors, suggesting that silencing of m iRNA m ay be a hallm ark of hum an cancers. MiRNA misexpression might be due to genetic m utations in m iRNA genes and their responsive elements in target genes. To test this hypothe sis, we plan to identify genetic m utations in selected hum an miRNA genes and their respons ive elements in targ et genes in 75 OC tumor tissues and correlate somatic m utations in m iRNA genes and their responsive elements in target genes with poor clinical outcome in EOC.
BODY
In the past one year, w e have successfu lly sequenced 50 m icroRNAs in 75 OC t umor tissues. So far, seven novel som atic m utations were observed in seven prim ary or precursor miRNA genes. We will continue to p erform sequencing analysis in m ore m icroRNAs in the next 6 months.
It is hypothesized that the presence of genetic variants in pri-or pre-m iRNA, but not within the mature miRNA itself, could affect their secondary structure and thereby block processing into functional m ature miRNA. To test this hypothesis, we used RNAHyb rid to predict and calculate the m ost stable second ary RNA structure with the lowest f ree energy for the variant and the wildtype pre-hsa-miR-188. From the predicted secon dary structures, a structure change was observed in the pre-hsa-miR-188 A allele com pared to the G allele ( Figure) . The G allele c reated a ba sepairing, which strengthen the stability of the stem and changes the second ary structure of this premiRNA. The optim al free energy was increased from -39.20 Kcal/Mol for A allele to -41.60 kcal/Mol for G allele, suggesting a more stab le second ary structure for G allele than A allele. P rocessing of miRNA precursors by the RNase Drosha requ ires the secondary hairpin structure characteristic of these RNA molecules and sp ecific sequ ence elem ents within the primiRNA. To assess the effect of the predicted changes in secondary structure on m ature miRNA expression, we clone d a wild-type or variant hsa-miR-188 miRNA gene into the pcDNA3.1 expression plasmid (Invitrogen, CA) and transfected the constructs into P C-3 prostate can cer cell line. The expression levels of m ature m iRNAs were m easured by Taqman based m icroRNA assays (Applied Bi osystems). We found that the expression levels of m ature hsa-miR-188 in the varian t miRNA gene were over 3 tim es higher than those in wild-type. Using the PITA prediction algorithm, MLH1 and MSH2 are predicted as targ ets for hsa-miR-188. Therefore, our results suggest that a functional somatic mutation in the pre-miR-188 gene might alter the expression of m ature m iRNA and, thereby, contribute to ova rian tumor developm ent a nd cancer progression through regulating key ovarian cancer related genes.
KEY RESEARCH ACCOMPLISHMENTS
We have successfully sequenced 50 microRNAs in 75 OC tumor tissues. So far, seven novel somatic mutations were observed in seven primary or precursor miRNA genes.
WE found a functional som atic mutati on in m iR-188. This m utation could alter the expression of mature miRNA and, thereby, co ntribute to ovarian tum or development and cancer progression through regulating key ovarian cancer related genes.
REPORT OUTCOME
We are in the preparation of a manuscript to report our findings.
